In vitro studies showed that nilotinib could effectively interrupt Col1-mediated tumorous DDR1 phosphorylation, thus impairing its downstream CXCL8 up-regulation and the increased neutrophil chemotaxis to HCC cells (Fig. 6A–C). This evidence concerns the gene DDR1 and hepatocellular carcinoma.